Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Theranostics|June 5, 2026
Development and in vivo evaluation of 18F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoringMichael Willmann, Jens P Bankstahl, Frank M Bengel, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 26, 2023
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspectiveHolger Scheible, Hanno Schieferstein, Ralf Schmidt, et al.Journal of Medicinal Chemistry|February 2, 2023
Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal TumorsAndreas Blum, Dieter Dorsch, Nina Linde, et al.Clinical Pharmacology in Drug Development|May 29, 2025
Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 StudyJayaprakasam Bolleddula, Holger Scheible, Florian Huber, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 16, 2026
Identification, structural elucidation and nonclinical characterization of oxMET1: A further major metabolite of xevinapant?Benedikt Lang, Hanno Schieferstein, Holger Scheible, et al.Journal of Medicinal Chemistry|August 30, 2021
PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer's Disease and Other TauopathiesHeiko Kroth, Felix Oden, Jerome Molette, et al.European Journal of Medicinal Chemistry|August 11, 2020
Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([18F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer's disease and other tauopathiesEmanuele Gabellieri, Francesca Capotosti, Jerome Molette, et al.Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 3, 2019
Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathiesHeiko Kroth, Felix Oden, Jerome Molette, et al.Clinical Pharmacology and Therapeutics|November 29, 2023
Non-Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion PieceGraeme C Young, Douglas K Spracklin, Alexander D James, et al.Pageof 3